Fusion Antibodies (LSE:FAB) 6-Month Share Buyback Ratio: -8.34% (As of Sep. 2025 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Fusion Antibodies 6-Month Share Buyback Ratio?

Fusion Antibodies LSE:FAB -21.28% 6-Month Share Buyback Ratio is -8.34 as of Sep. 2025. The stock has 4 warning signs investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Fusion Antibodies's current 6-Month Share Buyback Ratio was -8.34%.

Fusion Antibodies  (LSE:FAB) 6-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Fusion Antibodies 6-Month Share Buyback Ratio Related Terms

LSE:FAB vs VRTX, REGN, MRNA: 6-Month Share Buyback Ratio Comparison

For the Biotechnology subindustry, Fusion Antibodies's 6-Month Share Buyback Ratio, along with its competitors' market caps and 6-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fusion Antibodies 6-Month Share Buyback Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fusion Antibodies's 6-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Fusion Antibodies's 6-Month Share Buyback Ratio falls into.


Fusion Antibodies 6-Month Share Buyback Ratio Calculation

Fusion Antibodies's 6-Month Share Buyback Ratio for the quarter that ended in Sep. 2025 is calculated as

6-Month Share Buyback Ratio=(Shares Outstanding (EOP) (Mar. 2025 ) - Shares Outstanding (EOP) (Sep. 2025 )) / Shares Outstanding (EOP) (Mar. 2025 )
=(104.90212 - 113.656253) / 104.90212
=-8.35%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a 6-Month Share Buyback Ratio of -8.34 mean?
Fusion Antibodies (LSE:FAB) has a 6-Month Share Buyback Ratio of -8.34 as of Sep. 2025. The 6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. View historical data for Fusion Antibodies and its competitors.
Is Fusion Antibodies' 6-Month Share Buyback Ratio too high?
Fusion Antibodies' current 6-Month Share Buyback Ratio is -8.34.
How does Fusion Antibodies' 6-Month Share Buyback Ratio compare to VRTX and REGN?
Fusion Antibodies' 6-Month Share Buyback Ratio of -8.34 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Share Buyback Ratio for a Biotechnology company?
A good 6-Month Share Buyback Ratio depends on the Biotechnology industry context. However, 6-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Share Buyback Ratio mean?
A high 6-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. View historical data for Fusion Antibodies and its competitors. Fusion Antibodies's current 6-Month Share Buyback Ratio is -8.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fusion Antibodies stock overvalued right now?
Based on GuruFocus' analysis, Fusion Antibodies (LSE:FAB) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.04, compared to a current price of £0.09 — trading 131.3% above its estimated fair value. The current 6-Month Share Buyback Ratio is -8.34. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Share Buyback Ratio calculated?
6-Month Share Buyback Ratio is calculated from a company's financial statements. For Fusion Antibodies (LSE:FAB), the current 6-Month Share Buyback Ratio is -8.34 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Fusion Antibodies Business Description

Address 1 Springbank Road, Springbank Industrial Estate, Dunmurry, Northern Ireland, Belfast, GBR, BT17 0QL
Fusion Antibodies PLC is a Contract Research Organisation (CRO) providing antibody identification, engineering, and expression services for the discovery and development of antibodies for human and veterinary therapeutics, as well as for diagnostics. Its customers are pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company's three core service areas include: Discovery (identification, screening, and sequencing of novel antibodies); Engineering (optimising the performance of antibodies); and Supply (production and purification of antibodies for further development). Geographically company generates the majority of its revenue from North America and the Rest of the World, followed by the United Kingdom and the Rest of Europe.